A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection

Ileus Clinical Trial

Official title:

An Investigator-Sponsored, Open-Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04100447
• Other study ID #: LBS-IST-POI-101
• Status: Completed
• Phase: Phase 1
• Start date: November 5, 2018
• Est. completion date: December 1, 2020

Study information

• Verified date: December 2020
• Source: Centinela Hospital Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of LB1148 in subjects undergoing elective bowel resection. During abdominal surgery, surgeons handle, manipulate, and often make incisions in the bowel. These actions can create bruising, lesions, and microscopic damage to the bowel, which may allow digestive enzymes to cross the intestinal mucosal barrier potentially resulting in injury both locally and remotely. Leaking digestive enzymes may delay return of normal gastrointestinal (GI) function, lead to a lack of motility in the intestine (ileus), and promote the formation of intestinal scar tissue (adhesions).

Description:

The intestinal mucosal barrier plays a key role in both acute critical care medical conditions as well as burdensome chronic diseases. Healthy maintenance of the intestinal mucosal barrier requires oxygenation and blood flow and avoidance of mechanical or physical injury. Potent digestive enzymes are maintained within the intestine as long as normal blood flow continues and no damage or disturbances to the wall occur. Breakdown of the intestinal mucosal barrier can be produced by wide variety of events. These include prolonged low blood pressure (e.g. during shock), disruption of blood flow (e.g. during ischemia), and physical and mechanical perturbations (e.g. during trauma or abdominal surgery). One of the key advances toward the use of LB1148 to reduce postoperative complications was the learning that with more subtle perturbations of the mucosal barriers, such as during abdominal surgery, intraluminal pancreatic digestive enzymes played a role in GI dysfunction. Perioperative oral administration of LB1148 in preclinical models was sufficient to reduce the delayed return of GI function. Furthermore, the reduction in pancreatic digestive enzyme-induced tissue damage resulted in a profound reduction in postoperative adhesion formation. Together, these preclinical studies provide evidence that blocking pancreatic digestive enzymes with LB1148 in the intestine reduces local tissue damage, preserves GI function, and reduces adhesion formation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: December 1, 2020
• Est. primary completion date: March 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subjects will be eligible for participation in the study only if they meet ALL of the

following inclusion criteria:

1. Scheduled to undergo an elective (non-emergent) bowel resection. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elected indication.

2. The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.

Exclusion Criteria:

• Subjects will not be eligible for participation in the study if they meet ANY of the

following exclusion criteria:

1. Subjects who are < 18 or > 85 years of age.

2. Subjects who require emergency bowel surgery.

3. Subjects who have had 2 or more abdominal surgeries, excluding the current, for inflammatory bowel disease (IBD), including, but not limited to, IBD, Crohn's Disease, or ulcerative colitis. Note: This does not apply to previous surgeries such as hernia repair unrelated to IBD.

4. Subjects who meet the American Society of Anesthesiologists (ASA) definition for Class 4 or 5 disease.

5. Known inability to take the study drug orally (i.e. complete small bowel obstruction).

6. Subjects with contraindications or potential risk factors to taking TXA. These

include:

1. Known sensitivity to TXA

2. Recent craniotomy (past 30 days)

3. Active cerebrovascular bleed

4. Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome)

5. Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction

6. Continuing use of a combined hormonal contraceptive and/or combined hormonal replacement therapy (including combined hormonal pill, patch, or vaginal ring).

7. Subjects who have the following risk factors for thromboembolic disease:

1. Known medical history of congenital or acquired thrombophilia such as, but

not limited to:

• Sickle cell disease
• Nephrotic syndrome
• Factor V Leiden
• Prothrombin gene mutation
• Protein C or S deficiency
• Antithrombin III deficiency
• Antiphospholipid syndrome

2. Neurologic paresis, partial paralysis, or paralysis

3. Presence of a pacemaker

4. History of pulmonary embolism, deep vein thrombosis, cerebrovascular accident, or retinal venous/arterial occlusion.

8. History of or current seizure disorder.

9. Subjects with myeloproliferative disorders.

10. Subjects with a Body Mass Index (BMI) > 40.

11. Any other condition that, in the opinion of the Investigator, would preclude the subject from being an appropriate candidate for the study, including severe renal or hepatic impairment.

12. Planned treatment with alvimopan (Entereg®) during study participation period.

13. Subjects who have received any other investigational therapy within 4 weeks.

14. Subjects with a history of chronic opioid usage, defined by the American Pain Society as daily or near-daily use of opioids for at least 90 days.

15. Female subjects of childbearing potential with a positive urine or serum pregnancy test or who are not taking (or not willing to take) acceptable birth control measures (abstinence, intrauterine device, contraceptive implant or barrier method) through Study Day 30. Additionally, those women who are lactating and insist on breast feeding within 5 days of the last dose of study drug, are excluded.

16. Subjects with a known history of radiation enteritis.

Related Conditions & MeSH terms

• Adhesions
• Ileus
• Tissue Adhesions

Intervention

Drug:
• Tranexamic Acid
A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.

Locations

Country	Name	City	State
United States	Centinela Hospital Medical Center	Inglewood	California

Sponsors (1)

Lead Sponsor	Collaborator
Ronald Hurst, MD, FACS

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of participants who experience treatment-emergent adverse events (TEAEs)	The number of participants who experience treatment-emergent adverse events (TEAEs) with Investigator-specified relationship to LB1148 and assessment of severity	From first study drug dosing through Day 30
Secondary	Number of participants who require a nasogastric (NG) tube placement	Necessity for nasogastric (NG) tube placement	During hospitalization (up to 14 days postoperatively), yes or no
Secondary	Average length of time an NG tube was in place, if required	Time NG tube was in place, if needed	During hospitalization (up to 14 days postoperatively), in hours
Secondary	Number of participants who experience post surgical vomiting	Presence of postsurgical vomiting	During hospitalization (from surgical closure to up to 14 days postoperatively), yes or no
Secondary	Average number of vomiting episodes, when present	Number of vomiting episode(s)	During hospitalization (from surgical closure to up to 14 days postoperatively), number of total episodes
Secondary	Average time to first flatus following surgery	Time to first flatus	During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary	Average time to first bowel movement following surgery	Time to first bowel movement	During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary	Average time to tolerate a liquid diet following surgery	Time to toleration of a liquid diet	During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary	Average time to tolerate a solid diet after surgery	Time to toleration of a solid diet	During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary	Average time to hospital discharge order	Time to hospital discharge order written	During hospitalization (from admission to up to 14 days postoperatively), in hours